Journal
FRONTIERS IN ENDOCRINOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2018.00530
Keywords
gastric bypass surgery; beta cell function; glucagon-like peptide 1 (GLP-1); bile acids; microbiome; sodium glucose transporter 1 (SGLt1); type 2 diabetes
Categories
Funding
- National Institutes of Health (NIH) [R01DK067561, P30DK26687-30, P30DK063608]
- National Center for Advancing Translational Sciences, NIH [UL1TR001873]
- Federation Francophone de Recherche sur le Diabete (FFRD)
Ask authors/readers for more resources
Roux-en-Y gastric bypass results in large and sustained weight loss and resolution of type 2 diabetes in 60% of cases at 1-2 years. In addition to calorie restriction and weight loss, various gastro-intestinal mediated mechanisms, independent of weight loss, also contribute to glucose control. The anatomical re-arrangement of the small intestine after gastric bypass results in accelerated nutrient transit, enhances the release of post-prandial gut hormones incretins and of insulin, alters the metabolism and the entero-hepatic cycle of bile acids, modifies intestinal glucose uptake and metabolism, and alters the composition and function of the microbiome. The amelioration of beta cell function after gastric bypass in individuals with type 2 diabetes requires enteric stimulation. However, beta cell function in response to intravenous glucose stimulus remains severely impaired, even in individuals in full clinical diabetes remission. The permanent impairment of the beta cell may explain diabetes relapse years after surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available